



**FOR IMMEDIATE RELEASE**

January 10, 2007

**Media Contact**

Andy Cutler  
Cutler and Company, LLC  
andy@cutlerandcompany.com  
401.743.7842 (cell)

**Stryker Corporation Makes Investment in Afferent Corporation**

**Providence, RI (January 10, 2007)** — Afferent Corporation, an early-stage medical device company focused on treating neurologic dysfunction, announced today an investment by Stryker Corporation (NYSE: SYK). As part of the transaction, Stryker will also have access to certain aspects of Afferent’s technology.

“We are very pleased to establish this working relationship with Stryker,” stated David M. Hable, President and CEO of Afferent. “Their interest in Afferent serves to confirm the clinical and commercial opportunities of our technology and the strength of our team.”

The investment will be used to support Afferent’s ongoing research and development efforts and general operations.

**About Afferent Corporation**

Afferent Corporation, based in Providence, Rhode Island, is pioneering the development of a new class of medical devices to treat chronic neurologic dysfunction. Its lead technology enhances the function of mechanoreceptor cells involved in sensory perception as a means to restore brain function following stroke, to address complications resulting from diabetic neuropathy, and to improve elderly balance. Afferent’s development efforts are being pursued in collaboration with leading biomedical and clinical researchers throughout the United States. Building on this technology platform, Afferent aims to establish a leadership position in the emerging field of neurotherapeutic devices.